Comparison Between Quadro-iliac Plane Block (QIPB) and Supra-Inguinal Fascia Iliaca Compartment Block (S-FICB) for Total Hip Arthroplasty

NCT07667218 | Not Yet Recruiting

• 1 other identifier: QİPB vs S-FICB
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This randomized clinical trial aims to evaluate and compare the analgesic efficacy and functional outcomes of the quadro-iliac plane block (QIPB) and the supra-inguinal fascia iliaca compartment block (S-FICB) in patients undergoing total hip arthroplasty. The primary outcome is the Numeric Rating Scale (NRS) within the first 48 hours after surgery. Secondary outcomes include postoperative total opioid consumption, ıncidence of quadriceps motor block, time to first ambulation, block performance time, falls, length of hospital stay, block- related complications(hematoma,local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, and incidence of postoperative nausea and vomiting.

Conditions

Quadro-Iliac Plane Block; Supra-inguinal Fascia Iliaca Block; Hip Arthroplasty, Total; Pain Management

Keywords

QİPB; S-FICB; HİP; PAİN; ARTHROPLASTY

Outcome Measures

Primary Outcomes (1)

• Postoperative pain scores

  Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores at rest will be recorded in the post-anesthesia care unit and at postoperative 6, 24, 36, and 48 hours. Pain scores during movement will be assessed during passive flexion of the operated hip at postoperative 6, 24, 36, and 48 hours.

  Postoperative 6, 24, 36, and 48 hours

Secondary Outcomes (9)

• Postoperative opioid consumption

  Postoperative 24 and 48 hours

• Incidence of quadriceps motor block

  Postoperative 3, 6, and 24 hours

• Time to first ambulation

  Time from the end of surgery to the first successful ambulation.

• Patient satisfaction

  Postoperative 48 hours

• Postoperative nausea and vomiting (PONV)

  Postoperative 48 hours

Study Arms (2)

quadro-iliac plane block (QIPB)

ACTIVE COMPARATOR

Procedure: Quadro iliac Plane Block(QİPB)

supra-inguinal fascia iliaca compartment block (S-FICB)

ACTIVE COMPARATOR

Procedure: supra-inguinal fascia iliaca compartment block (S-FICB)

Interventions

Quadro iliac Plane Block(QİPB) PROCEDURE

Participants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.

quadro-iliac plane block (QIPB)

supra-inguinal fascia iliaca compartment block (S-FICB) PROCEDURE

Participants allocated to the S-FICB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.

supra-inguinal fascia iliaca compartment block (S-FICB)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 80 years
• American Society of Anesthesiologists physical status I-III
• Scheduled for elective unilateral primary total hip arthroplasty
• Surgery planned under spinal anesthesia
• Ability to understand and use the Numeric Rating Scale
• Written informed consent provided

You may not qualify if:

• Refusal to participate
• Revision total hip arthroplasty
• Bilateral total hip arthroplasty
• Contraindication to spinal anesthesia
• Contraindication to peripheral nerve block
• Known allergy to local anesthetics or study drugs
• Coagulopathy or anticoagulant use incompatible with neuraxial/regional anesthesia
• Infection at the block injection site
• Pre-existing neurological deficit involving the operative lower extremity
• Peripheral neuropathy
• Chronic opioid use
• Cognitive impairment or inability to communicate reliably
• Severe hepatic or renal failure
• Body mass index \>35 kg/m²
• Pregnancy

Sponsors & Collaborators

• Antalya City Hospital: lead

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

ENES ESKİN, CONSULTANT ANESTHESİOLOGİST

CONTACT

+905454738489; eneskin61@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: CONSULTANT ANESTHESİOLOGİST

Study Record Dates

• First Submitted: June 13, 2026
• First Posted: June 24, 2026
• Study Start (Estimated): November 15, 2026
• Primary Completion (Estimated): August 15, 2027
• Study Completion (Estimated): September 15, 2027
• Last Updated: June 24, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share